国际放射医学核医学杂志
國際放射醫學覈醫學雜誌
국제방사의학핵의학잡지
INTERNATIONAL JOURNAL OF RADIATION MEDICINE AND NUCLEAR MEDICINE
2015年
2期
140-143
,共4页
胡小春%蒋宁一%李敬彦%张弘%刘生%卢献平%梁九根%张占磊
鬍小春%蔣寧一%李敬彥%張弘%劉生%盧獻平%樑九根%張佔磊
호소춘%장저일%리경언%장홍%류생%로헌평%량구근%장점뢰
硒%碘放射性同位素%格雷夫斯病%甲状腺过氧化物酶抗体
硒%碘放射性同位素%格雷伕斯病%甲狀腺過氧化物酶抗體
서%전방사성동위소%격뢰부사병%갑상선과양화물매항체
Selenium%Iodine radioisotopes%Graves disease%Thyroid peroxidase antibody
目的 探讨Graves病患者经131I治疗后,补硒对患者血清甲状腺过氧化物酶抗体(TPOAb)水平的影响.方法 选取TPOAb水平为10～ 1300 IU/ml的Graves病患者266例,其中,TPOAB范围在10～60 IU/ml为阴性,TPOAb＞60 IU/ml为阳性.将所有患者随机分成对照组(112例)和硒治疗组(154例),对照组经131I治疗后行常规治疗,硒治疗组经131I治疗后行常规治疗及服硒制剂(100μg/次,2次/d),比较两组治疗后6、12个月TPOAb水平及TPOAb阳性率的变化.结果 治疗后6个月,两组TPOAb水平较治疗前均明显上升,且差异有统计学意义(对照组:Z=-2.084,P＜0.05;硒治疗组:Z=-2.112,P＜0.05),但两组之间的差异无统计学意义(Z=-0.764,P＞0.05);治疗后12个月,对照组TPOAb水平与治疗前相比差异无统计学意义(Z=-1.538,P＞0.05),硒治疗组TPOAb水平与治疗前相比差异有统计学意义(Z=-5.465,P＜0.01),两组间比较差异有统计学意义(Z=-2.180,P＜0.05);两组TPOAb水平阳性率在治疗后6、12个月与治疗前相比无明显变化(对照组:x21=0.720、x22=0.103,P均＞0.05;硒治疗组:x21=0.023、x22=0.340,P均＞0.05),两组间比较差异亦无统计学意义(x21=0.001、x22=0.366,P均＞0.05).结论 补硒能有效降低经131I治疗的Graves病患者的血清TPOAb水平,对血清高水平TPOAb的降低尤为明显.
目的 探討Graves病患者經131I治療後,補硒對患者血清甲狀腺過氧化物酶抗體(TPOAb)水平的影響.方法 選取TPOAb水平為10～ 1300 IU/ml的Graves病患者266例,其中,TPOAB範圍在10～60 IU/ml為陰性,TPOAb＞60 IU/ml為暘性.將所有患者隨機分成對照組(112例)和硒治療組(154例),對照組經131I治療後行常規治療,硒治療組經131I治療後行常規治療及服硒製劑(100μg/次,2次/d),比較兩組治療後6、12箇月TPOAb水平及TPOAb暘性率的變化.結果 治療後6箇月,兩組TPOAb水平較治療前均明顯上升,且差異有統計學意義(對照組:Z=-2.084,P＜0.05;硒治療組:Z=-2.112,P＜0.05),但兩組之間的差異無統計學意義(Z=-0.764,P＞0.05);治療後12箇月,對照組TPOAb水平與治療前相比差異無統計學意義(Z=-1.538,P＞0.05),硒治療組TPOAb水平與治療前相比差異有統計學意義(Z=-5.465,P＜0.01),兩組間比較差異有統計學意義(Z=-2.180,P＜0.05);兩組TPOAb水平暘性率在治療後6、12箇月與治療前相比無明顯變化(對照組:x21=0.720、x22=0.103,P均＞0.05;硒治療組:x21=0.023、x22=0.340,P均＞0.05),兩組間比較差異亦無統計學意義(x21=0.001、x22=0.366,P均＞0.05).結論 補硒能有效降低經131I治療的Graves病患者的血清TPOAb水平,對血清高水平TPOAb的降低尤為明顯.
목적 탐토Graves병환자경131I치료후,보서대환자혈청갑상선과양화물매항체(TPOAb)수평적영향.방법 선취TPOAb수평위10～ 1300 IU/ml적Graves병환자266례,기중,TPOAB범위재10～60 IU/ml위음성,TPOAb＞60 IU/ml위양성.장소유환자수궤분성대조조(112례)화서치료조(154례),대조조경131I치료후행상규치료,서치료조경131I치료후행상규치료급복서제제(100μg/차,2차/d),비교량조치료후6、12개월TPOAb수평급TPOAb양성솔적변화.결과 치료후6개월,량조TPOAb수평교치료전균명현상승,차차이유통계학의의(대조조:Z=-2.084,P＜0.05;서치료조:Z=-2.112,P＜0.05),단량조지간적차이무통계학의의(Z=-0.764,P＞0.05);치료후12개월,대조조TPOAb수평여치료전상비차이무통계학의의(Z=-1.538,P＞0.05),서치료조TPOAb수평여치료전상비차이유통계학의의(Z=-5.465,P＜0.01),량조간비교차이유통계학의의(Z=-2.180,P＜0.05);량조TPOAb수평양성솔재치료후6、12개월여치료전상비무명현변화(대조조:x21=0.720、x22=0.103,P균＞0.05;서치료조:x21=0.023、x22=0.340,P균＞0.05),량조간비교차이역무통계학의의(x21=0.001、x22=0.366,P균＞0.05).결론 보서능유효강저경131I치료적Graves병환자적혈청TPOAb수평,대혈청고수평TPOAb적강저우위명현.
Objective To explore the effect of additional selenium on the serum levels of thyroid peroxidase antibody (TPOAb) after treatment of Graves disease with 131I.Methods A total of 266 patients with TPOAb levels between 10 and 1300 IU/ml participated in this study.TPOAb levels within 10 IU/ml to 60 IU/ml were considered negative,and levels greater than 60 IU/ml were considered positive.All patients were randomly divided into control (n=112) and selenium treatment group (n=154).After treatment with 131I,the control group received conventional therapy,whereas the selenium treatment group received additional selenium (100 μg twice a day).The TPOAb levels and positive ratios of the two groups were compared with pre-therapy levels after treatment for 6 and 12 months.Results After 6 months,the TPOAb levels in both groups significantly increased compared with the pre-therapy levels (control group:Z=-2.084,P＜0.05;selenium treatment group:Z=-2.112,P＜0.05).However,no significant difference existed in the TPOAb levels between the two groups (Z=-0.764,P＞0.05).After 12 months,the TPOAb levels in the control group did not change significantly compared with the pre-therapy levels(Z=-1.538,P＞ 0.05),whereas the TPOAb levels in the selenium treatment group significantly decreased compared with the pre-therapy levels (Z=-5.465,P＜0.01).The difference between the two groups were statistically significant (Z=-2.180,P＜0.05).The positive ratios of TPOAb for both groups did not change significantly 6 or 12 months after 131I therapy (control group:x21 =0.720,x22 =0.103,both P＞0.05;selenium treatment group:x21 =0.023,x22 =0.340,both P＞0.05).Overall,the positive ratios were not statistically significant between the two groups (x21=0.001,x22=0.366,both P＞0.05).Conclusion Additional treatment with selenium after 131I therapy for Graves disease can effectively decrease the TPOAb levels,especially for patients with high initial TPOAb levels.
